Ascentage Pharma Group International American Depository Shares (AAPG) vs Damora Therapeutics (DMRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Damora Therapeutics (DMRA) has outperformed Ascentage Pharma Group International American Depository Shares (AAPG) over the past year, gaining 93.1% versus a loss of 60.1%. Ascentage Pharma Group International American Depository Shares is the larger company by market cap ($1.38 billion vs $1.30 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AAPG | DMRA |
|---|---|---|
| Share price | $14.75 | $21.08 |
| Market cap | $1.38B | $1.30B |
| 1-day change | +1.37% | +2.53% |
| YTD return | -43.79% | -10.65% |
| 1-year return | -60.15% | +93.05% |
| 5-year return | — | -75.95% |
| EPS (TTM) | $-2.26 | $-0.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $37.50 | $38.33 |
| 52-week low | $14.46 | $4.95 |
| Distance from 52-week high | -60.67% | -45.00% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +219.53% | +122.44% |
| Average volume | 6.37K | 531.94K |
| Shares outstanding | 93.39M | 61.74M |
| Employees | 828 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DMRA has outperformed AAPG by 153.2 percentage points over the past year.
About Ascentage Pharma Group International American Depository Shares
AAPG stock →Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation.
Health Care · Biotechnology: Pharmaceutical Preparations · 828 employees
About Damora Therapeutics
DMRA stock →Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
AAPG vs DMRA FAQ
Which is bigger, Ascentage Pharma Group International American Depository Shares or Damora Therapeutics?
Ascentage Pharma Group International American Depository Shares (AAPG) is larger, with a market capitalization of $1.38B compared with $1.30B for Damora Therapeutics (DMRA).
Which stock has performed better over the past year, AAPG or DMRA?
DMRA returned +93.05% over the past 12 months, compared with -60.15% for AAPG (price return, excluding dividends). Past performance does not predict future results.
Are Ascentage Pharma Group International American Depository Shares and Damora Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.